fbpx

Day

december 4, 2017
Funds will support Phase 2 study of Reltecimod for Acute Kidney Injury; Phase 3 study of Reltecimod for Necrotizing Soft Tissue Infections (“flesh eating bacteria”) ongoing Ness Ziona, Israel and Chapel Hill, NC – December 4, 2017 – Atox Bio, a clinical stage biotechnology company developing novel therapies for critically ill patients, today announced that...

Nyheder

Lundbeckfonden øger kendskab til hjernepris med stor kampagne
23. februar 2021
75 mio. kr. til dansk hjerneforskning i Aarhus
9. februar 2021
Hjernestimulation skal lindre symptomer ved Parkinsons sygdom
25. januar 2021

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge